|Articles|May 15, 2003

BioPharm International-05-01-2003
Volume 16
Issue 5

A Statistical Method to Account for Plate-to-Plate Variability in Multiple-Plate Bioassays

Author(s)Steven Walfish, Jeffrey B. Birch, James D. Williams

by James D. Williams, Virginia Polytechnic Institute and State University, Jeffrey B. Birch, and Steven Walfish Statistics don't lie, but if you don't include appropriate data, the resulting statistical analyses can be misleading. In biopharmaceutical development, if the variability from several different microplates is not addressed, assays testing the relative potency against a standard can be inaccurate. A statistical method that accounts for plate-to-plate heterogeneity is needed ? and presented here.

To view a PDF of this article from the BioPharm International archives, click this link

Articles in this issue

over 23 years ago

Article

Demonstrating the Consistency of Small Data Sets: Application of the Weisberg t-test for Outliers

over 23 years ago

Article

Sumeria to Satellites: Evolution of the Bioreactor

over 23 years ago

Article

Patent Law: Extracting Maximum Value from Your Patent Portfolio

over 23 years ago

Article

Inside Washington: Medication Safety in the Limelight

over 23 years ago

Article

Part 11 Is Not Going Away: The New Electronic Records Draft Guidance

over 23 years ago

Article

Survival Strategies: The Life Sciences Industry Turns to eLearning

over 23 years ago

Article

Analytical Advances: Collaborative Effort Results in Automated Cell Culture System

Stay at the forefront of biopharmaceutical innovation. Subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Related to this article

November 11th, 2026

The BioPharm Brief: Base Editing Hits Its Mark in Sickle Cell, a Phase 3 Win in Sjögren’s, and Off-the-Shelf CAR-T in Lupus

Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.

November 11th, 2026

Q&A: Who Is Accountable When AI Gets Drug Development Wrong?

Matt Truppo, Richard Jaenisch, and Brian Drapeau examine AI's impact on drug success, human oversight, data governance, and biopharma's future.

ProBio licenses a discovery-stage oncology antibody to AbTis, which plans to develop it as a bispecific, site-specific antibody-drug conjugate. Credit: Stock.Adobe.com/AddMeshCube

November 11th, 2026

ProBio Licenses Oncology Antibody to AbTis for Site-Specific ADC

ProBio grants AbTis exclusive global rights to a discovery-stage oncology antibody for development as a site-specific antibody-drug conjugate.

3D illustration of a translucent blue human torso, viewed from the front, with both kidneys highlighted in pink and the rib cage, liver, and intestines faintly visible. | Image Credit: © Sebastian Kaulitzki - stock.adobe.com

November 11th, 2026

ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months

ImvivaBio’s off-the-shelf CD19/BCMA CAR-T cell therapy CTA313 kept 88% of evaluable patients with refractory lupus in DORIS remission at Month 12, according to longer-term phase 1 data presented at ACR Convergence 2026.

Beam plans to file the first U.S. application for a base-editing therapy after BEACON met its primary endpoint in sickle cell disease. Credit: Stock.Adobe.com/freshidea

November 11th, 2026

Beam's Risto-cel Meets Primary Endpoint in Sickle Cell Trial

Beam’s base-edited cell therapy met its primary endpoint in the BEACON trial, and a U.S. biologics license application is planned as early as year-end.

Close-up photograph of a person using their fingers to hold open a reddened eye while squeezing a drop from a small white-and-blue dropper bottle into it. | Image Credit: © TatjanaMeininger - stock.adobe.com

November 11th, 2026

Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial

Full phase 3 OASIZ-301 results show both dosing regimens of Amgen’s CD40L antagonist fusion protein dazodalibep reduced systemic disease activity in Sjögren’s disease at Week 48. The every-four-weeks dose also improved patient-reported dryness.

After a three-year research collaboration, AstraZeneca has acquired Omniose, whose platform builds conjugate vaccine components inside one E. coli cell. Credit: Stock.Adobe.com/Valeriya Zankovych

November 10th, 2026

AstraZeneca Acquires Omniose, Adding Bioconjugate Vaccine Platform

AstraZeneca acquired preclinical biotech Omniose, adding a bioconjugation platform for conjugate vaccines against serious bacterial infections.

November 10th, 2026

The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide

FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.

A Statistical Method to Account for Plate-to-Plate Variability in Multiple-Plate Bioassays

Articles in this issue

Related to this article

Trending on BioPharm International

AstraZeneca Acquires Omniose, Adding Bioconjugate Vaccine Platform

Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial

ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months

The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide

Efinopegdutide Meets Primary Endpoint in Phase 2b MASH Trial